- Home
- About Us
- Service
- Application
- Technology
- Contact Us
HapOnco® mClean
HapOnco® mClean
Exclusively Designed, Precisely Monitored, Fully Protected
Product Introduction
HapOnco® mClean Fixed MRD Testing Series is a fixed MRD testing product independently developed by HaploX, designed for patients with lung cancer, Digestive Tract cancer, Hepatobiliary and Pancreatic cancer The HapOnco® mClean Fixed MRD Testing Series product carefully selects important genes related to lung cancer, gastrointestinal tumors, and hepatopancreatobiliary tumors. Relying on the company's self - developed LIUDUS® molecular diagnostic technology platform and core bioinformatics technology, it accurately monitors ultra - low - frequency molecular residues, which can indicate the risk of recurrence in patients, and also assist in the selection of clinical targeted drugs and the evaluation of therapeutic effects, providing patients with a more comprehensive MRD protection plan.
Product Advantages
（1）High specificity: MRD gene panels specifically designed for patients with lung cancer/gastrointestinal tumors/hepatopancreatobiliary tumors.
（2）Comprehensive: A more comprehensive MRD protection plan that covers multiple dimensions such as targeted/immune drug selection and genetic risk assessment.
Applicable Population
Exclusively designed for patients with lung cancer / Digestive Tract cancer / Hepatobiliary and Pancreatic cancer
Patients who need to evaluate treatment efficacy after radical treatment
Patients who cannot obtain tissue samples but still need dynamic monitoring of recurrence
Patients who need to obtain key medication-related genes and monitor recurrence over the long term
Patients who have achieved complete remission after treatment and need to formulate medication plans based on long-term residual tumor status in the body
Address
Units 610, 6/F, Building 16W, Phase 3, HongKong Science Park, New Territories, HongKong
Phone
+852 69410851
customer_service@haplox.net
© 2025 HaploX Ltd. All Rights Reserved.
